ACADIA Pharmaceuticals (NASDAQ:ACAD) Issues Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Key Points

• ACADIA reported quarterly EPS of $0.31, beating analysts’ $0.20 estimate, while revenue of $342.3 million exceeded consensus and rose 22.8% year over year.
• The company raised its 2026 DAYBUE sales outlook to $505 million–$520 million, but narrowed NUPLAZID guidance to $760 million–$775 million.
• A Phase II Alzheimer’s psychosis trial narrowly missed its primary endpoint; ACADIA plans to advance the 60 mg dose into Phase III. The company ended the quarter with $976 million in cash.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.20 by $0.11, FiscalAI reports. The firm had revenue of $342.30 million during the quarter, compared to the consensus estimate of $332.58 million. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%. The firm's quarterly revenue was up 22.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.42 earnings per share.

Here are the key takeaways from ACADIA Pharmaceuticals' conference call:

• ACADIA reported $342 million in Q3 revenue, up 22% year over year on an adjusted basis. DAYBUE sales reached a record $140 million, up 39%, while NUPLAZID generated $202 million, up 12%; growth for both brands was largely volume-driven.
• ACADIA raised its 2026 DAYBUE sales guidance to $505 million–$520 million, citing STIX momentum, with more than half of U.S. patients using the formulation by quarter-end. The company also highlighted its Germany launch and a newly allowed U.S. patent expected to protect both formulations through March 2041, while reiterating its $700 million sales ambition for 2028.
• NUPLAZID guidance was narrowed to $760 million–$775 million, with management citing the time needed for its expanded sales force to build prescribing relationships. ACADIA maintained its ambition of approximately $1 billion in NUPLAZID sales by the end of 2028.
• The phase II RADIANT trial of remlifanserin in Alzheimer’s disease psychosis narrowly missed statistical significance on its primary endpoint (p=0.0603), although the 60 mg dose showed activity across four efficacy scales and a nominally significant result on a key secondary endpoint. ACADIA plans to advance the 60 mg dose and adjust trial conduct and statistical methods for phase III; the primary endpoint remains unchanged.
• ACADIA expects phase II results for remlifanserin in Lewy body dementia psychosis and for ACP-211 in major depressive disorder in the second half of 2027, extending the timeline for pipeline updates. The company ended the quarter with $976 million in cash.

ACADIA Pharmaceuticals Stock Performance

NASDAQ ACAD traded up $0.90 on Wednesday, reaching $21.47. The stock had a trading volume of 4,719,887 shares, compared to its average volume of 1,533,597. ACADIA Pharmaceuticals has a 12-month low of $18.39 and a 12-month high of $30.96. The business's 50-day moving average price is $23.20 and its 200 day moving average price is $23.64. The stock has a market cap of $3.70 billion, a P/E ratio of 9.67 and a beta of 0.87.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on ACAD shares. BMO Capital Markets reduced their price objective on shares of ACADIA Pharmaceuticals from $36.00 to $34.00 and set an "outperform" rating for the company in a research report on Thursday, September 24th. Oppenheimer restated a "market perform" rating on shares of ACADIA Pharmaceuticals in a report on Wednesday, September 23rd. Weiss Ratings raised shares of ACADIA Pharmaceuticals from a "hold (c)" rating to a "hold (c+)" rating in a research report on Wednesday, August 12th. Morgan Stanley lifted their price target on shares of ACADIA Pharmaceuticals from $27.00 to $28.00 and gave the stock an "equal weight" rating in a research note on Tuesday, August 25th. Finally, UBS Group cut shares of ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price target for the company from $49.00 to $23.00 in a research report on Tuesday, October 13th. Thirteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $31.34.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other news, EVP Mark Schneyer sold 3,321 shares of the firm's stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $20.88, for a total transaction of $69,342.48. Following the transaction, the executive vice president directly owned 71,322 shares in the company, valued at approximately $1,489,203.36. This trade represents a 4.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 26.20% of the company's stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system and neuropsychiatric disorders. The company's research programs target conditions with significant unmet medical needs, including neurological and rare neurodevelopmental diseases.

ACADIA's commercial products include NUPLAZID (pimavanserin), an atypical antipsychotic approved in the United States to treat hallucinations and delusions associated with Parkinson's disease psychosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.